All articles by Vemula Pravalika
Vemula Pravalika
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN’s extensive distribution network and support infrastructure with ALPCO-GeneProof’s innovative molecular diagnostic technologies.
Revvity Unveils a New Era of Automated Tuberculosis Testing
Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer.
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study.
AIRS Medical Accelerates Global Expansion with MRI AI Solution SwiftMR™ Supply Contracts in Germany and the UK
AIRS Medical Inc., a leading provider of AI-powered healthcare solutions, recently announced that it has signed supply contracts in Germany and the UK. Following these contracts, the company plans to expedite its overseas market penetration and solidify its presence in European markets.
Covid-19 spurred on the self-testing revolution
Thanks to Covid-19, self-testing has become a common practice. Throughout the next few years, experts believe that this will continue to gain prominence.
ReadyGo Diagnostics Ltd. Announces its Partnership with Porex for Global Sampler Production
ReadyGo Diagnostics initiates volume manufacturing of its sample collection and preparation device with Porex.
The British In Vitro Diagnostics Association (BIVDA) has released new three-year strategy, ‘Diagnostics for All’
The British In Vitro Diagnostics Association (BIVDA) have released new three-year strategy, ‘Diagnostics for All’.
P95 Expands Its Global Presence with a New USA Office
P95, a leading global provider of clinical and epidemiology services focused on vaccines and infectious diseases, has opened its first office in the USA. Based in the Research Triangle Park in North Carolina, the largest research park in the USA, this expansion underlines P95s commitment to delivering high-quality research solutions to our clients and partners across the globe.
Beckman Coulter’s Dxl 9000 Immunoassay Analyzer Extends Menu With New CE-Marked Hepatitis Assays at ESCMID Global
Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced today, ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays. Recently, tests for Hepatitis B and C viruses — namely Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays — received CE marks.